Krystal Biotech (KRYS)
NASDAQ:KRYS
KRYS Stock Chart & Stats
$251.40
-$3.73(-2.33%)
At close: 4:00 PM EST
$251.40
-$3.73(-2.33%)
Day’s Range― - ―
52-Week Range$122.80 - $298.30
Previous CloseN/A
Volume44.50K
Average Volume (3M)295.57K
Market Cap
$7.35B
Enterprise Value$6.69B
Total Cash (Recent Filing)$827.79M
Total Debt (Recent Filing)$9.34M
Price to Earnings (P/E)34.7
Beta0.74
Next Earnings
May 11, 2026EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.70
Shares Outstanding29,232,190
10 Day Avg. Volume291,406
30 Day Avg. Volume295,568
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue17.18
Enterprise Value/Gross Profit18.55
Enterprise Value/Ebitda39.84
Forecast
1Y Price Target
$325.00Price Target Upside29.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)7.62
Revenue Forecast (FY)$523.69M
Bulls Say, Bears Say
Bulls Say
Clinical Catalyst — KB801 Dosing RegimenAnalyst views upcoming KB801 trial results as a major catalyst because a simpler, home‑friendly dosing schedule could capture patients from competing therapies with heavier administration burdens.
Commercial Adoption And ReimbursementAnalyst highlights that broadened reimbursement approvals and a regulatory label allowing home self‑dosing should expand the eligible patient pool and support sustained commercial momentum.
International ExpansionAnalyst expects ex‑US launches of Vyjuvek across Europe and Japan, supported by an expanding distributor network, to drive material revenue growth as payer agreements progress.
Bears Say
Clinical Tolerability And Trial DelaysAnalyst flags that increased dosing frequency in ocular programs raises tolerability concerns and may necessitate trial re‑enrollment, risking slower development timelines and delayed approvals.
Pricing And Reimbursement RiskAnalyst warns that ongoing pricing negotiations and potential price resets in key European markets could delay revenue recognition and pressure realized pricing.
Valuation And Pipeline RiskAnalyst recommends waiting for additional pipeline de‑risking because the current valuation appears to price broad program success, limiting upside if clinical or commercial setbacks occur.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $122.80 and its highest was $298.30 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $7.35B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is May 11, 2026 which is in 44 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Feb 17, 2026. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.544 by $0.156.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.5.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,232,190 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.7 in its last earnings report, beating expectations of $1.544. Following the earnings report the stock price went up 4.12%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$325.00 (29.28% Upside)
$325.00 (29.28% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 18.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.36%
12-Months-Change
Fundamentals
Return on Equity
18.69%
Trailing 12-Months
Asset Growth
26.33%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial momentum and strong financial results (notably $107.1M Q4 revenue, 34% Y/Y full-year growth, 94% gross margin, and ~$956M cash) together with important pipeline breakthroughs (KB407 CF transduction data) and regulatory designations (RMAT, Fast Track). Key risks include rising operating expenses, higher COGS for non-U.S. sales, ongoing pricing negotiations in Europe that create near-term revenue visibility risk, and operational/compliance frictions in early international launches. On balance, the positive commercial traction, strong margins and cash position, and multiple promising clinical developments outweigh the operational and timing headwinds described.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$325.00
▲(29.28% Upside)
Technical Analysis
Alkermes
―
PTC Therapeutics
―
Crispr Therapeutics AG
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---